The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of prostate cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer.
FDA Approves Drug for Patients with Advanced Prostate Cancer
Posted by worldpharmanews 612 days ago (http://www.worldpharmanews.com)Who Voted for this Story
Comments